Phase 4
Completed N=12
Gene Regulation by Thiazolidinediones
Source: ClinicalTrials.gov NCT00567593 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
May 2014
Primary outcomePrimary: PDK4 mRNA — .776; 1.30 copies/nL — p=.01
Summary
The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PDK4 mRNA |
.776; 1.30 | .01 sig |
Eligibility Criteria
Inclusion Criteria
- Capable of giving informed consent
- Agrees to use a barrier method of birth control for the duration of the study
Exclusion Criteria
- History of inflammatory bowel disease
- Has taken prescription or over the counter medications in the two weeks prior to enrollment
- History of diabetes, heart failure, angina, hypertension, coronary heart disease, cancer, bleeding disorder, HIV, AIDS
- Fasting LDL >160 mg/dl
- History of smoking in the year prior to enrollment
- Pregnant or breastfeeding
Data sourced from ClinicalTrials.gov (NCT00567593). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.